San Francisco, June 1, 2022 – Recardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with Recardio’s pivotal Heal-MI Phase 3 trial design with Dutogliptin in Acute Myocardial Infarction.
Recardio’s Positive Phase 2 Results presented as Latebreaker at World Congress on Heart Failure 2022 in Madrid
San Francisco, May 23, 2022 – Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the positive study results of Recardio’s Phase 2 clinical study in Acute Myocardial Infarction were presented on Saturday, May 21, 2022, during the Latebreaker Session at the World Congress on Acute Heart Failure 2022 in Madrid.
Recardio at BIO-Europe Spring 2022
San Francisco, March 28, 2022 – Recardio Inc., a late stage clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, is participating at the BIO-Europe Spring 2022.
Read MoreRecardio at J.P. Morgan Conference 2022
San Francisco, January 10, 2022 – Recardio Inc., a late-stage clinical-stage life science company focusing on therapies for cardiovascular diseases, is participating in the 40th Annual J.P. Morgan Healthcare Conference in San Francisco.
Read More